Tag Archives: GlaxoSmithKline plc (GSK)

Novartis to acquire all remaining rights to Ofatumumab from GlaxoSmithKline plc (GSK)

Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully human monoclonal antibody for relapsing remitting multiple sclerosis (RRMS) which targets CD20 and … Read the full press release